HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Bristol Myers Squibb Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Bristol Myers Squibb Intelligence Report

Generated from 44 signals · 8 evidence sources

Type

Company Intelligence Report

Generated

Aug 1, 2026

Confidence

Moderate Confidence · 67%

Evidence

248 items

Sources

70

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Bristol Myers Squibb maintains an active intelligence profile across Oncology, Immunomodulator, Hematology, Multiple Myeloma, Neuroscience. 44 signals are linked with 3 investigate-priority items requiring leadership attention. Competitive pressure is moderate with high portfolio impact. Evidence coverage stands at 67% across 8 tracked sources. Highest-priority development: FDA Accepts Supplemental Application for Emgality (Galcanezumab) by Eli Lilly. Portfolio development. FDA Accepts Supplemental Application for Emgality (Galcanezumab) by Eli Lilly is an owned Bristol Myers Squibb portfolio development in Neurology · CGRP Inhibitor.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. investigateJun 20, 2026

    RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization

    Oncology · Multiple Myeloma · opportunity score 174

    View detail
  2. investigateJun 17, 2026

    Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

    Oncology · Melanoma · opportunity score 174

    View detail
  3. investigateJun 17, 2026

    Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis

    Oncology · Ovarian Cancer · opportunity score 168

    View detail
  4. portfolio

    FDA Accepts Supplemental Application for Emgality (Galcanezumab) by Eli Lilly

    FDA approval

    View detail
  5. portfolio

    FDA Grants Priority Review for KISQALI FEMARA Co-Packaged Product

    FDA approval

    View detail
  6. portfolio

    AstraZeneca's AZD0120 Phase I Study in Multiple Myeloma Initiated

    Phase III success

    View detail
  7. portfolio

    Novartis Evaluates Remibrutinib for Secondary Progressive Multiple Sclerosis

    Phase III success

    View detail
  8. portfolio

    Study on Managing Hyperlipidemia in ALK+ NSCLC Patients on Lorlatinib

    Portfolio development

    View detail
  9. portfolio

    Study on Managing Hyperlipidemia in ALK+ NSCLC Patients on Lorlatinib

    Portfolio development

    View detail
  10. portfolio

    Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough

    Phase III success

    View detail
  11. portfolio

    Study on Managing Hyperlipidemia in ALK+ NSCLC Patients on Lorlatinib

    Portfolio development

    View detail
  12. portfolio

    AstraZeneca's Anifrolumab Study for Systemic Lupus Erythematosus Underway

    FDA approval

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 7368 with buyer quality 10 (Enterprise). Competitive pressure: Moderate. Portfolio impact: High. 3 investigate-priority signals warrant near-term portfolio review. Competitiva linkage surfaces 3 competitive findings requiring monitoring.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025

    Moderate Confidence · 63%

    Potential competitive pressure

    Source: Bristol Myers Squibb, Competitiva

    View evidence

  • Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma

    High Confidence · 88%

    Limited competitive pressure indicated

    Source: Humanexa Signals, Competitiva

    View evidence

  • Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma

    Moderate Confidence · 81%

    Limited competitive pressure indicated

    Source: ClinicalTrials.gov, Competitiva

    View evidence

  • FDA Accepts Supplemental Application for Emgality (Galcanezumab) by Eli Lilly

    Low Confidence · 0%

    FDA approval

    Source: Humanexa Signals, FDA, Portfolio

    View evidence

  • FDA Grants Priority Review for KISQALI FEMARA Co-Packaged Product

    Low Confidence · 0%

    FDA approval

    Source: Bristol Myers Squibb, FDA, Portfolio

    View evidence

  • AstraZeneca's AZD0120 Phase I Study in Multiple Myeloma Initiated

    Low Confidence · 0%

    Phase III success

    Source: Bristol Myers Squibb, ClinicalTrials.gov, Portfolio

    View evidence

  • Novartis Evaluates Remibrutinib for Secondary Progressive Multiple Sclerosis

    Low Confidence · 0%

    Phase III success

    Source: Humanexa Signals, ClinicalTrials.gov, Portfolio

    View evidence

  • Study on Managing Hyperlipidemia in ALK+ NSCLC Patients on Lorlatinib

    Low Confidence · 0%

    Portfolio development

    Source: Humanexa Signals, ClinicalTrials.gov, Portfolio

    View evidence

  • Study on Managing Hyperlipidemia in ALK+ NSCLC Patients on Lorlatinib

    Low Confidence · 0%

    Portfolio development

    Source: ClinicalTrials.gov, ClinicalTrials.gov, Portfolio

    View evidence

  • Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough

    Low Confidence · 0%

    Phase III success

    Source: Bristol Myers Squibb, ClinicalTrials.gov, Portfolio

    View evidence

  • Study on Managing Hyperlipidemia in ALK+ NSCLC Patients on Lorlatinib

    Low Confidence · 0%

    Portfolio development

    Source: ClinicalTrials.gov, ClinicalTrials.gov, Portfolio

    View evidence

  • AstraZeneca's Anifrolumab Study for Systemic Lupus Erythematosus Underway

    Low Confidence · 0%

    FDA approval

    Source: Bristol Myers Squibb, ClinicalTrials.gov, Portfolio

    View evidence

  • Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Investigational New Drug (IND) Application

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — INREBIC (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation

    Neurology · Alzheimer's Disease

  • RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization

    Oncology · Multiple Myeloma

  • Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

    Oncology · Melanoma

  • FDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride)

    Hematology · Myelofibrosis

  • Bristol-Myers Squibb Evaluates Pumitamig vs Pembrolizumab in NSCLC Trial

    Oncology · Non-Small Cell Lung Cancer

  • FDA Accepts Supplement Application for YERVOY (ipilimumab)

    Oncology · Immune Checkpoint Inhibitor

  • CMP-001 and Nivolumab Show Promise in Advanced Melanoma Phase 2/3 Trial

    Oncology · Melanoma

  • FDA Grants Priority Review for KISQALI FEMARA Co-Packaged Product

    Oncology · Combination Therapy

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.